In this episode of the Endpoints, Dr. Steve Perrin, CSO at the ALS Therapy Development Institute, sits down to talk about AMX0035, a drug consisting of a combination of two small molecule compounds: sodium phenylbutyrate and tauroursodeoxycholic acid (TUDCA). Amylyx, the sponsor of AMX0035, recently completed enrollment of a 132 participant phase 2 trial.

To learn more about the ALS Therapy Development Institute and our mission to end ALS, click here.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.